UY32008A - Composición farmacéutica - Google Patents

Composición farmacéutica

Info

Publication number
UY32008A
UY32008A UY32008A UY32008A UY32008A UY 32008 A UY32008 A UY 32008A UY 32008 A UY32008 A UY 32008A UY 32008 A UY32008 A UY 32008A UY 32008 A UY32008 A UY 32008A
Authority
UY
Uruguay
Prior art keywords
active ingredient
pharmaceutically active
pharmaceutical composition
stabilizing
present
Prior art date
Application number
UY32008A
Other languages
English (en)
Inventor
Nonomura Muneo
Hiraishi Yasuhiro
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41327301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32008(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY32008A publication Critical patent/UY32008A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención provee una composición farmacéutica o una preparación sólidas que contiene un ingrediente farmacéuticamente activo estabilizando y un método para estabilizar la misma. De acuerdo con la presente invención, una composición farmacéutica puede estabilizarse al contener un ingrediente farmacéuticamente activo no peptídico que tiene un grupo amino primario o secundario, un excipiente y un compuesto acídico. Además, una preparación sólida que contiene un ingrediente farmacéuticamente activo, óxido de titanio, un plastificante y un ácido orgánico de cadena puede aumentar la estabilidad del ingrediente farmacéuticamente activo durante una irradiación luminosa.
UY32008A 2008-07-28 2009-07-27 Composición farmacéutica UY32008A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008194219 2008-07-28

Publications (1)

Publication Number Publication Date
UY32008A true UY32008A (es) 2010-02-26

Family

ID=41327301

Family Applications (1)

Application Number Title Priority Date Filing Date
UY32008A UY32008A (es) 2008-07-28 2009-07-27 Composición farmacéutica

Country Status (29)

Country Link
US (2) US9186411B2 (es)
EP (2) EP2564833B1 (es)
JP (2) JP5295356B2 (es)
KR (1) KR20110042334A (es)
CN (3) CN102743330B (es)
AR (1) AR072842A1 (es)
AU (1) AU2009277443A1 (es)
BR (1) BRPI0916689A2 (es)
CA (2) CA2936400C (es)
CL (1) CL2011000170A1 (es)
CO (1) CO6290638A2 (es)
CR (1) CR20110110A (es)
DO (2) DOP2011000033A (es)
EA (2) EA201170272A1 (es)
EC (1) ECSP11010855A (es)
ES (2) ES2669592T3 (es)
GE (2) GEP20146122B (es)
IL (2) IL210735A0 (es)
MA (1) MA32556B1 (es)
MX (1) MX2011000757A (es)
MY (2) MY169461A (es)
NZ (2) NZ591344A (es)
PE (3) PE20141585A1 (es)
SG (1) SG186685A1 (es)
TW (2) TW201431552A (es)
UA (1) UA103332C2 (es)
UY (1) UY32008A (es)
WO (1) WO2010013823A2 (es)
ZA (1) ZA201101198B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2814466B1 (en) 2012-02-15 2018-12-26 Takeda Pharmaceutical Company Limited Tablet comprising 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamide or a salt thereof
CN104582687A (zh) * 2012-06-27 2015-04-29 武田药品工业株式会社 用盐稳定的胺和有机酸的液体制剂
US9555115B2 (en) * 2012-09-19 2017-01-31 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration with improved dissolution and/or absorption
US20150080845A1 (en) * 2013-03-14 2015-03-19 Allergan, Inc. Polymer system for securing implants in syringe needles
CN105330647A (zh) * 2014-08-14 2016-02-17 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
CN105985278A (zh) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
MA41850A (fr) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
PE20180605A1 (es) 2015-07-30 2018-04-09 Takeda Pharmaceuticals Co Tableta
CN105106203B (zh) * 2015-08-17 2019-04-05 江苏豪森药业集团有限公司 富马酸沃诺拉赞的药物组合物及其制备方法
CN105030725B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶组合物及其制备方法
CN105030720B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶片及其制备方法
CN107224438B (zh) * 2016-03-25 2021-04-06 江苏豪森药业集团有限公司 富马酸沃诺拉赞药物组合物
US11331316B2 (en) * 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
CN106580903B (zh) * 2016-11-17 2019-12-13 江苏豪森药业集团有限公司 罗红霉素缓释药物组合物
CN106860852A (zh) * 2017-02-17 2017-06-20 王清华 一种用于结合治疗胃病的粘液西药
US10603292B2 (en) 2017-05-31 2020-03-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
SG11202000136YA (en) 2017-07-10 2020-02-27 Takeda Pharmaceuticals Co Preparation comprising vonoprazan
CN108558831B (zh) * 2018-06-08 2021-07-27 上海璃道医药科技有限公司 取代吡咯-4-烷基胺类化合物及其用途
CN109288722B (zh) * 2018-11-09 2021-03-30 伯德创研(广州)生物科技有限公司 一种变色修正肤色的粉底及其制备方法
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
CN111973565A (zh) * 2020-07-07 2020-11-24 南京海纳医药科技股份有限公司 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途
CN114853728B (zh) * 2022-05-07 2023-11-07 四川制药制剂有限公司 一种富马酸伏诺拉生片及其制备方法
CN115364065B (zh) * 2022-08-23 2024-03-15 宁波高新区美诺华医药创新研究院有限公司 富马酸伏诺拉生片
CN117462507B (zh) * 2023-12-28 2024-03-15 山东齐都药业有限公司 富马酸伏诺拉生药物组合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2844351B2 (ja) 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
US5834503A (en) 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
FR2752162B1 (fr) 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
JP4730985B2 (ja) 1997-09-10 2011-07-20 武田薬品工業株式会社 安定化された医薬製剤
ATE241341T1 (de) 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CA2404226A1 (en) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
CN1638773A (zh) * 2001-07-30 2005-07-13 三菱制药株式会社 以氨基苯磺酸衍生物作为活性成分的药物制剂
US20040258741A1 (en) * 2001-10-17 2004-12-23 Takaaki Terahara Percutaneous absorption preparations
US7247702B2 (en) 2002-02-28 2007-07-24 The Penn State Research Foundation Periocular drug delivery for diabetic retinopathy
ATE540943T1 (de) 2002-03-07 2012-01-15 Boehringer Ingelheim Pharma 3-ä(2-ää4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoümethylü-1-methyl-1h-benzimidazol-5- carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester methansulfonat
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
DE10233108A1 (de) * 2002-07-20 2004-01-29 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin und ein Lichtschutzmittel
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CA2531564C (en) 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
JP2005263788A (ja) 2004-02-17 2005-09-29 Sankyo Co Ltd インドリン化合物を含有する安定化された医薬組成物
JP5168712B2 (ja) 2004-04-01 2013-03-27 味の素株式会社 ナテグリニド含有製剤
JP2006001912A (ja) 2004-06-21 2006-01-05 Chugai Pharmaceut Co Ltd タンパク質製剤の安定化方法
US8048909B2 (en) 2004-09-30 2011-11-01 Takeda Pharmaceutical Company Limited Proton pump inhibitors
US20080050428A1 (en) 2004-10-05 2008-02-28 Altana Pharma Ag Oral Pharmaceutical Preparation Comprising a Proton Pump Antagonist and a Basic Excipient
CN101247801B (zh) 2005-08-25 2012-08-22 协和发酵生化株式会社 血中酒精浓度上升抑制用组合物
ES2391757T3 (es) * 2005-08-30 2012-11-29 Akeda Pharmaceutical Company Limited Derivados de 1-H-pirrol sustituidos con 1-heterociclilsulfonilo, 2-aminometilo, 5-heteroarilo como inhibidores de la secreción de ácido
BRPI0620788A2 (pt) 2005-12-28 2011-11-22 Takeda Pharmaceutical preparação sólida
CN101516367A (zh) * 2006-09-15 2009-08-26 安斯泰来制药有限公司 对光稳定的雷莫司琼的固态医药组合物
JP5074052B2 (ja) 2007-02-13 2012-11-14 有限会社愛和ライト 遊技機
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
CL2008002834A1 (es) 2007-09-28 2009-09-11 Takeda Pharmaceuticals Co Compuestos heterociclicos de 5 miembros, composicion farmaceutica, util para el tratamiento de la ulcera peptidica, sindrome de zollinger-ellison, gastritis, esofagitis por reflujo, enfermedad sintomatica por reflujo gastroesofagico, esofago de barrett, cancer gastrico, hiperacidez gastrica o ulcera debido a estres posquirurgico.
KR101559597B1 (ko) 2007-09-28 2015-10-12 다케다 야쿠힌 고교 가부시키가이샤 ５―원 헤테로시클릭 화합물
JPWO2009066746A1 (ja) 2007-11-22 2011-04-07 国立大学法人 東京大学 組織癒着防止材および関節拘縮防止材

Also Published As

Publication number Publication date
BRPI0916689A2 (pt) 2015-11-17
CR20110110A (es) 2011-04-28
ES2660962T3 (es) 2018-03-26
CN102743330A (zh) 2012-10-24
PE20110591A1 (es) 2011-09-15
TW201010992A (en) 2010-03-16
DOP2011000033A (es) 2011-04-15
ES2669592T3 (es) 2018-05-28
CA2732243A1 (en) 2010-02-04
GEP20146122B (en) 2014-07-25
PE20141585A1 (es) 2014-11-13
ECSP11010855A (es) 2011-03-31
EA201170272A1 (ru) 2011-10-31
UA103332C2 (ru) 2013-10-10
IL210735A0 (en) 2011-03-31
EP2564833B1 (en) 2017-12-20
CA2936400A1 (en) 2010-02-04
CN102743330B (zh) 2016-03-23
WO2010013823A2 (en) 2010-02-04
JP2013047239A (ja) 2013-03-07
JP2011529445A (ja) 2011-12-08
US9186411B2 (en) 2015-11-17
MA32556B1 (fr) 2011-08-01
EA201201451A1 (ru) 2013-07-30
DOP2013000172A (es) 2013-11-15
IL228817A0 (en) 2013-12-31
MY156305A (en) 2016-01-29
CL2011000170A1 (es) 2011-06-10
JP5593363B2 (ja) 2014-09-24
AR072842A1 (es) 2010-09-22
GEP20146166B (en) 2014-09-25
CO6290638A2 (es) 2011-06-20
EP2309985B1 (en) 2018-03-14
WO2010013823A3 (en) 2010-04-15
AU2009277443A1 (en) 2010-02-04
NZ602592A (en) 2014-01-31
CN102164581A (zh) 2011-08-24
PE20140977A1 (es) 2014-08-20
US20110124687A1 (en) 2011-05-26
CA2936400C (en) 2018-03-27
ZA201101198B (en) 2012-05-30
TW201431552A (zh) 2014-08-16
EP2564833A1 (en) 2013-03-06
CA2732243C (en) 2016-11-29
EP2309985A2 (en) 2011-04-20
JP5295356B2 (ja) 2013-09-18
SG186685A1 (en) 2013-01-30
MY169461A (en) 2019-04-11
CN104784180A (zh) 2015-07-22
MX2011000757A (es) 2011-02-24
KR20110042334A (ko) 2011-04-26
NZ591344A (en) 2013-03-28
US20130261156A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
UY32008A (es) Composición farmacéutica
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
CY1123023T1 (el) Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα
CY1115751T1 (el) Φαρμακευτικος συνδυασμος 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλπροπυλ)-φαινολης και ενος αντιεπιληπτικου
CY1119436T1 (el) Σκευασμα για αντισωμα εναντι- 4 7
EA201500871A8 (ru) Ингибиторы репликации вирусов гриппа
BR112014009146A8 (pt) formulações de etanercepte estabilizadas com aminoácidos
ECSP109984A (es) Composición farmacéutica mejorada que contiene dihidropiridina, antagonista del canal de calcio y el método para su preparación
UY32062A (es) Inhibidores de beta-secretasa
CL2011000314A1 (es) Composición farmacéutica estable que comprende linaclotida; método de preparación; y uso para preparar un medicamento útil para tratar un desorden gastrointestinal.
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
UY34880A (es) Preparación líquida
EA201190319A1 (ru) Твердая фармацевтическая композиция, содержащая ривароксабан
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
CY1123382T1 (el) Απο του στοματος και ενεσιμα και σκευασματα ενωσεων τετρακυκλινης
CO2019002246A2 (es) Compuesto heterocíclico nitrogenado bicíclico
EA201170512A1 (ru) Композиция для перорального введения
EA201291104A1 (ru) Пероральные лекарственные формы бендамустина
CY1122598T1 (el) Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης
EA201100104A1 (ru) Фармацевтическая композиция, содержащая статин
MX2021000769A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
MX2012007393A (es) Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam.
TN2011000030A1 (en) Pharaceutical composition
EA201391512A1 (ru) Твердая фармацевтическая композиция

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181108